Press Releases Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 01:20:00 14/05/26 am AEST			5-day change	1st Jan Change
299.20 ^DKK	+0.91%		+4.65%	-8.01%

14/05	Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring	RE
13/05	Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Ahead of US-China Meeting	MT

Press Releases

13/05	Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026	GL
13/05	Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons	GL
12/05	Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity	GL
12/05	Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity	GL
07/05	Novo Nordisk A/S : (tax report 2025 novo nordisk)	PU
07/05	Novo Nordisk A/S : (novo nordisk tax report 2025)	PU
06/05	Novo Nordisk: Q1 Earnings Snapshot	AQ
06/05	Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026	GL
06/05	Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026	AQ
05/05	Novo Nordisk A/S - share repurchase programme	GL
29/04	Health Canada approves 1st generic version of Ozempic in the country	AQ
28/04	Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity	GL
27/04	Novo Nordisk A/S - share repurchase programme	GL
23/04	Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes	GL
20/04	Novo Nordisk A/S - share repurchase programme	GL
20/04	Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease	GL
15/04	Novo Nordisk A/S : Presentation from Annual General Meeting 2026	PU
15/04	Novo Nordisk A/S : Minutes and voting results from Annual General Meeting 2026	PU
15/04	Novo Nordisk to collaborate with OpenAI to accelerate drug development	AQ
14/04	Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered	GL
13/04	Novo Nordisk A/S - share repurchase programme	GL
13/04	Novo Nordisk A/S : 2025 ( novo nordisk modern slavery statement 2025 )	PU
09/04	Novo Nordisk A/S: Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU	GL
07/04	Novo Nordisk A/S – Share repurchase programme	GL
02/04	Diabetes advocates cross their fingers as a bipartisan bill revives efforts to lower insulin costs	AQ